• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . Broad neutralizing antibody response of a monomeric spike-based SARS-CoV-2 bivalent vaccine against diverse variants

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A


. 2025 Sep 2;122(35):e2503254122.
doi: 10.1073/pnas.2503254122. Epub 2025 Aug 25. Broad neutralizing antibody response of a monomeric spike-based SARS-CoV-2 bivalent vaccine against diverse variants

Siling Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Hui Sun[SUP] #[/SUP][SUP] 1 2 [/SUP], Yizhen Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Zikang Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Lunzhi Yuan[SUP] #[/SUP][SUP] 1 2 [/SUP], Huilin Guo[SUP] #[/SUP][SUP] 1 2 [/SUP], Jiahua Gao[SUP] #[/SUP][SUP] 1 2 [/SUP], Miaolin Lan[SUP] 1 2 [/SUP], Yangtao Wu[SUP] 1 2 [/SUP], Huixian Shang[SUP] 1 2 [/SUP], Xiuting Chen[SUP] 1 2 [/SUP], Zheng Chen[SUP] 1 2 [/SUP], Jiayi Hu[SUP] 1 2 [/SUP], Zimin Tang[SUP] 1 2 [/SUP], Guiping Wen[SUP] 3 [/SUP], Dong Ying[SUP] 1 2 [/SUP], Chang Liu[SUP] 1 2 [/SUP], Yanan Jiang[SUP] 1 2 [/SUP], Jinfu Su[SUP] 1 2 [/SUP], Min Lin[SUP] 1 2 [/SUP], Ting Wu[SUP] 1 2 [/SUP], Shaowei Li[SUP] 1 2 [/SUP], Tianying Zhang[SUP] 1 2 [/SUP], Jun Zhang[SUP] 1 2 [/SUP], Yi Guan[SUP] 4 5 [/SUP], Ningshao Xia[SUP] 1 2 6 [/SUP], Quan Yuan[SUP] 1 2 [/SUP], Qingbing Zheng[SUP] 1 2 [/SUP], Yali Zhang[SUP] 1 2 [/SUP], Zizheng Zheng[SUP] 1 2 [/SUP]



Affiliations
Abstract

severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2) bivalent vaccines show potential against variants but lack a full understanding of the immunological mechanisms that drive broadly neutralizing antibodies (bnAbs). This study explored the immunogenicity of a bivalent vaccine in rhesus macaques, containing spike (S) proteins from the prototype (S[SUB]prototype[/SUB]) and chimeric S protein (S[SUB]1628x[/SUB]). The vaccine induced bnAbs against multiple variants, including challenging subvariants like EG.1, BA.2.86, and JN.1. The monomeric S protein exposed less accessible regions within the receptor-binding domain (RBD) "inner face" and "NTD face" and subdomains 1, eliciting a diverse array of bnAbs against various Omicron subvariants. Notably, antibodies targeting the conserved RBD inner face, such as 4A5, showed potent neutralization across all tested variants. Structural analyses provide insights into the broad protectiveness of these vaccine-elicited nAbs. This study underscores the potential of bivalent vaccines with monomeric spike proteins to confer broad-spectrum immunity, offering a promising direction for future SARS-CoV-2 universal vaccine design.

Keywords: SARS-CoV-2; bivalent vaccine; broad neutralizing antibody.

 
Back
Top Bottom